JP7041070B2 - Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 - Google Patents

Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 Download PDF

Info

Publication number
JP7041070B2
JP7041070B2 JP2018553876A JP2018553876A JP7041070B2 JP 7041070 B2 JP7041070 B2 JP 7041070B2 JP 2018553876 A JP2018553876 A JP 2018553876A JP 2018553876 A JP2018553876 A JP 2018553876A JP 7041070 B2 JP7041070 B2 JP 7041070B2
Authority
JP
Japan
Prior art keywords
alkyl
membered
optionally substituted
halo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018553876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513778A (ja
JP2019513778A5 (OSRAM
Inventor
エマーソン キャンベル ジョン
ウィリアム ダンカン ケネス
アリーン フォリー メーガン
マーティン ハーヴィー ダレン
ウェイン クンツ ケヴィン
エドワード ジョン ミルズ ジェームズ
ジョン マンチホフ マイケル
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2019513778A publication Critical patent/JP2019513778A/ja
Publication of JP2019513778A5 publication Critical patent/JP2019513778A5/ja
Priority to JP2022036728A priority Critical patent/JP7420847B2/ja
Application granted granted Critical
Publication of JP7041070B2 publication Critical patent/JP7041070B2/ja
Priority to JP2024002232A priority patent/JP2024045202A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2018553876A 2016-04-15 2017-04-17 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 Expired - Fee Related JP7041070B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022036728A JP7420847B2 (ja) 2016-04-15 2022-03-10 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2024002232A JP2024045202A (ja) 2016-04-15 2024-01-11 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662323602P 2016-04-15 2016-04-15
US62/323,602 2016-04-15
US201662348837P 2016-06-10 2016-06-10
US62/348,837 2016-06-10
US201662402997P 2016-09-30 2016-09-30
US62/402,997 2016-09-30
PCT/US2017/027918 WO2017181177A1 (en) 2016-04-15 2017-04-17 Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022036728A Division JP7420847B2 (ja) 2016-04-15 2022-03-10 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物

Publications (3)

Publication Number Publication Date
JP2019513778A JP2019513778A (ja) 2019-05-30
JP2019513778A5 JP2019513778A5 (OSRAM) 2020-05-28
JP7041070B2 true JP7041070B2 (ja) 2022-03-23

Family

ID=58664786

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553876A Expired - Fee Related JP7041070B2 (ja) 2016-04-15 2017-04-17 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2022036728A Active JP7420847B2 (ja) 2016-04-15 2022-03-10 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2024002232A Pending JP2024045202A (ja) 2016-04-15 2024-01-11 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022036728A Active JP7420847B2 (ja) 2016-04-15 2022-03-10 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2024002232A Pending JP2024045202A (ja) 2016-04-15 2024-01-11 Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物

Country Status (24)

Country Link
US (2) US20170355712A1 (OSRAM)
EP (1) EP3442947B1 (OSRAM)
JP (3) JP7041070B2 (OSRAM)
KR (2) KR102571679B1 (OSRAM)
CN (1) CN109153650A (OSRAM)
AU (3) AU2017250369A1 (OSRAM)
BR (1) BR112018071093A2 (OSRAM)
CA (1) CA3021062A1 (OSRAM)
CL (2) CL2018002928A1 (OSRAM)
CO (1) CO2018012181A2 (OSRAM)
DK (1) DK3442947T3 (OSRAM)
ES (1) ES2953512T3 (OSRAM)
FI (1) FI3442947T3 (OSRAM)
HU (1) HUE064145T2 (OSRAM)
IL (3) IL307931A (OSRAM)
LT (1) LT3442947T (OSRAM)
MA (1) MA44666A (OSRAM)
MX (2) MX395342B (OSRAM)
PL (1) PL3442947T3 (OSRAM)
PT (1) PT3442947T (OSRAM)
SG (2) SG10201913471VA (OSRAM)
SI (1) SI3442947T1 (OSRAM)
TW (1) TWI751155B (OSRAM)
WO (1) WO2017181177A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504715A (ja) * 2016-12-19 2020-02-13 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
JP2021500334A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291813A4 (en) 2015-05-06 2019-01-02 The Regents of The University of California K-ras modulators
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
WO2017201199A1 (en) 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
TW201900638A (zh) * 2017-04-20 2019-01-01 加州大學董事會 Ｋ－ｒａｓ調節劑
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN111343988A (zh) * 2017-10-17 2020-06-26 Epizyme股份有限公司 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
EP3697420A4 (en) * 2017-10-18 2021-11-24 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
BR112020007585A2 (pt) * 2017-10-18 2020-09-24 Epizyme, Inc. método para prevenir ou tratar um distúrbio sanguíneo, inibidor de ehmt2 e uso de um inibidor de ehmt2
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US20220296595A1 (en) * 2019-05-05 2022-09-22 Qilu Regor Therapeutics Inc. Cdk inhibitors
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US20230127046A1 (en) 2019-11-27 2023-04-27 Riken G9a INHIBITOR
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CU20220065A7 (es) 2020-05-04 2023-06-13 Amgen Inc Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
MX2023009685A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
WO2022175747A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CA3234693A1 (en) * 2021-10-15 2023-04-20 Tango Therapeutics, Inc. Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
JP2025523256A (ja) * 2022-07-20 2025-07-17 エス２シーバイオ・インコーポレイテッド ヘテロアリール誘導体化合物およびその用途
CN115947692B (zh) * 2022-12-28 2024-12-27 上海再启生物技术有限公司 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法
WO2024216164A1 (en) 2023-04-13 2024-10-17 Tango Therapeutics, Inc. N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer
WO2025045203A1 (zh) * 2023-09-01 2025-03-06 葆元生物医药科技(杭州)有限公司 杂环化合物及其中间体和应用

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535447A (ja) 2001-06-26 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
WO2006014420A1 (en) 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
JP2008540439A (ja) 2005-05-05 2008-11-20 サノフィ−アベンティス・ユー・エス・エルエルシー 安定なナノ粒子処方物
JP2009501164A (ja) 2005-07-15 2009-01-15 ４エスツェー アクチェンゲゼルシャフト ２−アリールベンゾチアゾール及びその使用
JP2009513703A (ja) 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
WO2009103652A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP2009538833A (ja) 2006-05-26 2009-11-12 アボット・ラボラトリーズ ポロ様キナーゼの阻害薬
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
JP2012501983A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー ４−アルキル−置換ジアミノピリミジン類
WO2012115479A2 (en) 2011-02-25 2012-08-30 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013033037A2 (en) 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
WO2013054351A1 (en) 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
JP2013530954A (ja) 2010-06-04 2013-08-01 エフ．ホフマン−ラ ロシュ アーゲー Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
JP2015518039A (ja) 2012-05-30 2015-06-25 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Ｆｇｆｒ阻害剤としてのプテリジン
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0585500A1 (en) * 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CN102066339B (zh) * 2008-04-16 2014-09-24 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2，6-二氨基-嘧啶-5-基甲酰胺类化合物
CA2732791A1 (en) * 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia
US20130244963A1 (en) * 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
KR101452235B1 (ko) * 2012-02-03 2014-10-22 서울대학교산학협력단 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
EP2828250B1 (en) * 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
US9676756B2 (en) * 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
ES2769648T3 (es) * 2014-06-16 2020-06-26 Fundacion Para La Investig Medica Aplicada Nuevos compuestos como inhibidores duales de histona metiltransferasas y ADN metiltransferasasASAS

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535447A (ja) 2001-06-26 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
WO2006014420A1 (en) 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
JP2008540439A (ja) 2005-05-05 2008-11-20 サノフィ−アベンティス・ユー・エス・エルエルシー 安定なナノ粒子処方物
JP2009501164A (ja) 2005-07-15 2009-01-15 ４エスツェー アクチェンゲゼルシャフト ２−アリールベンゾチアゾール及びその使用
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
JP2009513703A (ja) 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP2009538833A (ja) 2006-05-26 2009-11-12 アボット・ラボラトリーズ ポロ様キナーゼの阻害薬
WO2009103652A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP2012501983A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー ４−アルキル−置換ジアミノピリミジン類
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
JP2013530954A (ja) 2010-06-04 2013-08-01 エフ．ホフマン−ラ ロシュ アーゲー Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
WO2012115479A2 (en) 2011-02-25 2012-08-30 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013054351A1 (en) 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
WO2013033037A2 (en) 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
JP2015518039A (ja) 2012-05-30 2015-06-25 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Ｆｇｆｒ阻害剤としてのプテリジン
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Arvanitis, Elena A. et al，Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated Aromatic Nucleophilic Substitution，Journal of Combinatorial Chemistry ，2004年，6(3),，414-419
Lee, Jun A. et al，Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line，Journal of Enzyme Inhibition and Medicinal Chemistry ，2015年，30(4),，607-614
REGISTRY（STN）［online］，2015年，CAS 登録番号：1798663-30-5; 1798641-80-1; 1798521-49-9; 1798473-53-6
Wang, Jinhua et al，SnapShot: Kinase Inhibitors II，Molecular Cell ，2015年，58(4),，710-710.e1

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504715A (ja) * 2016-12-19 2020-02-13 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
JP2022110080A (ja) * 2016-12-19 2022-07-28 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
JP2021500334A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法

Also Published As

Publication number Publication date
AU2024200464A1 (en) 2024-02-15
IL281319A (en) 2021-04-29
IL281319B2 (en) 2024-03-01
JP2022081606A (ja) 2022-05-31
BR112018071093A2 (pt) 2019-01-29
CL2018002928A1 (es) 2019-02-01
US20210198277A1 (en) 2021-07-01
PT3442947T (pt) 2023-08-07
AU2017250369A1 (en) 2018-10-11
AU2021245168B2 (en) 2023-10-26
MX395342B (es) 2025-03-25
EP3442947B1 (en) 2023-06-07
MX2018012622A (es) 2019-08-29
JP2024045202A (ja) 2024-04-02
SI3442947T1 (sl) 2023-10-30
KR20180133906A (ko) 2018-12-17
IL307931A (en) 2023-12-01
IL262140A (en) 2018-11-29
LT3442947T (lt) 2023-09-11
MA44666A (fr) 2019-02-20
WO2017181177A1 (en) 2017-10-19
ES2953512T3 (es) 2023-11-14
JP7420847B2 (ja) 2024-01-23
JP2019513778A (ja) 2019-05-30
DK3442947T3 (da) 2023-09-04
MX2022010947A (es) 2022-09-21
KR102571679B1 (ko) 2023-08-29
CN109153650A (zh) 2019-01-04
AU2021245168A1 (en) 2021-11-04
US20170355712A1 (en) 2017-12-14
KR20230130747A (ko) 2023-09-12
IL281319B1 (en) 2023-11-01
CA3021062A1 (en) 2017-10-19
TWI751155B (zh) 2022-01-01
SG11201808799SA (en) 2018-11-29
CO2018012181A2 (es) 2019-08-20
SG10201913471VA (en) 2020-03-30
PL3442947T3 (pl) 2023-10-02
HUE064145T2 (hu) 2024-03-28
EP3442947A1 (en) 2019-02-20
CL2019000815A1 (es) 2019-08-16
FI3442947T3 (fi) 2023-08-24
TW201803854A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
JP7041070B2 (ja) Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
RU2722363C2 (ru) Замещенное производное 2н-пиразола
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
EP2855459B1 (en) Aminoquinazoline and pyridopyrimidine derivatives
KR20190092542A (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
JP2019533650A (ja) Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
JP7710756B2 (ja) Ｃｔｌａ－４低分子分解剤及びその使用
CA3046864C (en) Cdk4/6 inhibitor
HK40002420A (zh) 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物
HK40077297B (zh) 氮杂-喹啉化合物及其用途
OA19500A (en) Amine-substituted Aryl or Heteroaryl compounds as Ehmt1 and Ehmt2 inhibitors.
NZ787281A (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
HK40004853B (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
HK40004853A (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220310

R150 Certificate of patent or registration of utility model

Ref document number: 7041070

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees